Home » Business News » 2013 » March » March 6, 2013

Galapagos receives EUR7.5 million in Servier alliances

March 6, 2013 - Mechelen, Belgium

Galapagos NV (EURONEXT BRUSSELS: GLPG)today announcedthe achievement of milestones in the alliances with Servier inosteoarthritisand oncology. These milestones triggered payments to Galapagos totalingEUR7.5million, contributing to 2012 Group revenues.

The osteoarthritis (OA) alliance with Servier was initiated in July2010 todeliver new oral medicines. In October 2011 Galapagos announced asecondalliance with Servier for innovative treatments in oncology. In bothalliances,Galapagos is responsible for the discovery and development of newcandidatedrugs against novel targets. Galapagos is eligible to receive in excess ofEUR500million in success-based milestones, plus royalties on commercial sales.Thecompany also retains exclusive US commercialization rights to allcompoundsdiscovered.

"We are very proud to announce the delivery of high quality compoundsagainstour novel targets in both osteoarthritis and oncology," said Onno van deStolpe,CEO of Galapagos. "Our alliances are proving to be very productive,with atotal of eight pre-clinical candidates, 10 clinical programs, andtwoin-licensed programs delivered to alliance partners."

"We are very pleased with the progress of our alliances with Galapagos,"saidBernard Marchand, Head of Discovery Research at Servier. "We are confidentthatthey will continue to deliver results."

About Galapagos' osteoarthritis alliance with Servier

Servier and Galapagos entered into an alliance in July 2010 to develop neworalmedicines for the treatment of osteoarthritis (OA). Galapagos isresponsiblefor the discovery and development of new candidate drugs, and Servierhas anexclusive option to license these after the completion of Phase Iclinicaltrials. For any marketed products, Servier will have the rights todevelopment,registration and commercialization, but Galapagos retains exclusiveU.S.commercialization rights. Galapagos is also eligible to receivediscovery,development, regulatory and other milestone payments that could reachEUR290million, plus royalties upon commercialization of products outside theU.S.covered under the agreement.

About Galapagos' oncology alliance with Servier

In October 2011 Servier and Galapagos announced an alliance agreementbuildingon a combination of novel Galapagos and Servier targets in oncology.Galapagoswill be responsible for the discovery and development of new candidatedrugsagainst these targets. Servier will have an exclusive option to licenseeachprogram after the completion of pre-clinical development by Galapagos.Servierwill be responsible for further clinical development, registrationandcommercialization. Galapagos retains exclusive rights for clinicaldevelopment,registration and commercialization in the United States. Galapagos iseligibleto receive discovery, development, regulatory and other milestone paymentsthatcould reach EUR260 million, plus royalties upon commercialization ofproducts byServier.

About Servier

Servier is a privately-run research based pharmaceutical company with a2012turnover of EUR3.9 billion. Servier reinvests 25% of its turnover inResearch &Development in cardiovascular, metabolic, neurological, psychiatric andbone andjoint diseases as well as oncology. Servier is established in 140countriesworldwide with over 20,000 employees. More info at:

About Galapagos

Galapagos (EURONEXT BRUSSELS: GLPG) (PINKSHEETS: GLPYY) is specialized innovelmodes-of-action,with a large pipeline of four clinical, six pre-clinical, and 30discoverysmall-molecule and antibody programs in cystic fibrosis,inflammation,antibiotics, metabolic disease, and other indications.GLPG0634 is an orally-available, selective inhibitor of JAK1 for thetreatmentof rheumatoid arthritis and potentially other inflammatory diseases,about toenter Phase 2b studies. AbbVie and Galapagos signed a worldwidelicenseagreement whereby AbbVie will be responsible for furtherdevelopment andcommercialization after Phase 2b. Galapagos has another selectiveJAK1inhibitor in Phase 2 in lupus and psoriasis, GSK2586184 (formerlyGLPG0778,in-licensed by GlaxoSmithKline in 2012). GLPG0187 is a novel integrinreceptorantagonist currently in a Phase 1b patient study in metastasis. GLPG0974is thefirst inhibitor of GPR43 to be evaluated clinically for the treatment ofIBD;this program will start a Proof of Concept Phase 2 study in Q2 2013.The Galapagos Group, including fee-for-service companies BioFocus,Argenta andFidelta, has over 800 employees and operates facilities in five countries,withglobal headquarters in Mechelen, Belgium. Further information at:

Galapagos forward-looking statements

This release may contain forward-looking statements, including,withoutlimitation, statements containing the words "believes,""anticipates,""expects," "intends," "plans," "seeks," "estimates," "may," "will,""could,""stands to," and "continues," as well as similar expressions. Suchforward-looking statements may involve known and unknown risks,uncertainties and otherfactors which might cause the actual results, financial condition,performanceor achievements of Galapagos, or industry results, to be materiallydifferentfrom any historic or future results, financial conditions,performance orachievements expressed or implied by such forward-looking statements.Giventhese uncertainties, the reader is advised not to place any unduereliance onsuch forward-looking statements. These forward-looking statements speakonly asof the date of publication of this document. Galapagos expresslydisclaims anyobligation to update any such forward-looking statements in thisdocument toreflect any change in its expectations with regard thereto or anychange inevents, conditions or circumstances on which any such statement is based,unlessrequired by law or regulation.

Galapagos receives EUR7.5 million in Servier alliances:

This announcement is distributed by Thomson Reuters on behalf ofThomson Reuters clients. The owner of this announcement warrants that:

(i) the releases contained herein are protected by copyright and other applicable laws; and

(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Galapagos NV via Thomson Reuters ONE



Galapagos NV
Onno van de Stolpe
Chief Executive Officer
Tel: +31 6 2909 8028

Elizabeth Goodwin
Director Investor Relations
Tel: +31 6 2291 6240
Email Contact


Comment on this story